All News
Filter News
Found 177 articles
-
Peptide Cancer Vaccine Market Size, Share, Industry Growth, Trend, Business Opportunities, Challenges, Drivers and Restraint Research Report by 2027
2/10/2022
The industry analysis report is considered a valuable source of information about the global Peptide Cancer Vaccine industry and lays stress on the future market scope, emerging industry trends, industry statistics, and market growth potential during the forecast years.
-
ADDING and REPLACING Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
2/4/2022
ADDING and REPLACING Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021.
-
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
2/4/2022
Bristol Myers Squibb (NYSE:BMY) today reports results for the fourth quarter and full year of 2021, which reflect strong sales driven by robust commercial execution and significant advancement of the company’s pipeline that further progressed the company’s portfolio renewal.
-
Concentric Analgesics Announces Completion of $20 Million Financing and Appoints Two New Board Members as it Prepares to Initiate Registration-Enabling Phase 3 Studies for Vocacapsaicin
1/26/2022
Concentric Analgesics, Inc. today announced the closing of a $20 million convertible note financing from a combination of new and existing investors.
-
Cabaletta Bio Strengthens Executive Leadership Team with Promotions of Gwendolyn Binder, Ph.D. to President of Science and Technology and Arun Das, M.D. to Chief Business Officer
1/11/2022
Cabaletta Bio, Inc. today announced the promotions of Gwendolyn Binder, Ph.D. to President of Science and Technology and Arun Das, M.D. to Chief Business Officer.
-
Bristol Myers Squibb is dropping $920 million to acquire the exclusive global rights of Immatics' experimental cancer drug program, the companies announced Tuesday morning.
-
Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401
12/14/2021
Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, and Bristol Myers Squibb (NYSE: BMY), today announced that they have entered into a license, development and commercialization agreement (the “agreement”) for Immatics’ TCR Bispecific candidate, IMA401.
-
Awakn Life Sciences Appoints Former EVP & Chief Commercial Officer of Gilead Sciences, Paul Carter, as Independent Member of its Board of Directors
12/14/2021
Paul Carter is a seasoned international BioPharma leader with an outstanding and proven track record.
-
Immatics Announces Third Quarter 2021 Financial Results and Provides Business Update
11/16/2021
ImmaticsN.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today reported its financial results for the quarter ended September 30, 2021, and provided a business update on its progress over the reporting period.
-
Immatics Reports Clinical Responses across Multiple Solid Tumor Types in Ongoing ACTengine® IMA203 Phase 1a Trial Targeting PRAME
11/9/2021
Company to host conference call on Tuesday, November 9 at 8:30 am EST Dose escalation for cell therapy candidate ACTengine® IMA203 ongoing; dose level 3 completed at doses below 1 billion transduced cells
-
Immatics to Present Update on Lead ACTengine® Program IMA203 Targeting PRAME at the Society for Immunotherapy of Cancer’s 36th Annual Meeting
11/1/2021
Immatics N.V. today announced that the company will provide an update on its ACTengine® IMA203 trial in a late-breaking oral presentation as well as an update on Immatics’ next-generation CD8ab TCR-T approach at the 36th Annual Meeting of the Society for Immunotherapy of Cancer’s (SITC).
-
iOmx Therapeutics Raises EUR 65 million in Series B Round
10/5/2021
iOmx Therapeutics AG, a biopharmaceutical company developing cancer therapeutics based on next generation immune checkpoint targets, announced the closing of a Series B round totaling EUR 65 million.
-
Immatics Announces Second Quarter 2021 Financial Results and Provides Business Update
8/10/2021
ImmaticsN.V., a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, reported its financial results for the quarter ended June 30, 2021 and provided a business update on its progress over the reporting period.
-
BioCopy AG and Immatics enter into a collaboration to characterize T cell receptor - peptide-HLA interactions
7/7/2021
BioCopy AG announces a collaboration with Immatics N.V. "Immatics" in the field of characterization of T cell receptors.
-
Selexis and KBI Biopharma Enter into Agreements with Immatics for Integrated Approach to Advance Immatics TCR Bispecific Program Towards IND
6/29/2021
Selexis SA and KBI Biopharma announced today that they have signed service agreements with Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies.
-
BioSpace Movers & Shakers, May 28
5/28/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Immatics Announces Changes to its Board of Directors - May 26, 2021
5/26/2021
Tuebingen, Germany and Houston, Texas, May26, 2021 – Immatics N.V., a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced changes to its Board of Directors.
-
Immatics Announces First Quarter 2021 Financial Results and Business Update
5/18/2021
Data update for ongoing ACTengine® IMA200 clinical trial seriesdemonstratedfirst anti-tumor activity in heavily pre-treated solid cancer patients during early phases of dose escalation
-
Immatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Program IMA402 Targeting PRAME
5/11/2021
Immatics’ second TCR Bispecifics program IMA402 demonstratestumor cell killing in vitro and complete regressions of established tumors in anin vivo tumor model
-
TScan Therapeutics Appoints Katina Dorton, J.D., M.B.A., to Its Board of Directors
3/23/2021
TScan Therapeutics, Inc. a biopharmaceutical company focused on the development of T-cell receptor engineered T cell therapies for the treatment of patients with cancer, announced the appointment of Katina Dorton, J.D., M.B.A., to its Board of Directors.